Long-lasting MS treatment

Israeli biotech Mapi has developed a formulation of Glatiramer Acetate that Multiple Sclerosis patients only need take once a month, rather than daily. Glatiramer Acetate Depot is still in Phase 3 trials but Mapi has already sold the marketing rights to multinational giant Mylan.

https://www.timesofisrael.com/mylan-buys-rights-to-israel-developed-ms-treatment/

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.